Updated:
Revvity
Revvity Inc. is a US-based global corporation founded in 1937. It offers analytical instruments, medical imaging components, and software instruments to...
Revvity
Revvity Inc. is a US-based global corporation founded in 1937. It offers analytical instruments, medical imaging components, and software instruments to clients. The company operates in the biotech and life science sector.
General information
Firm type
Asset Manager
Year founded
1937
Location
Region
North America
Country
United States
City
Waltham
Corporate office
Waltham, MA, United States
Principals
Prahlad Singh
President and Chief Executive Officer
Sector focus
Frequently asked questions
What is Revvity's exposure to pharmaceutical R&D spending cycles?
Roughly 85% of revenue ties directly to pharmaceutical and biotech R&D budgets, making Revvity more cyclically exposed than diversified tools peers. During pharma pipeline contractions, consumables pull-through and instrument orders have historically declined; conversely, strong NME approval cycles drive growth in its high-content screening and automation divisions.
How does the BioLegend acquisition fit into Revvity's longer-term strategy?
The $5.25 billion BioLegend acquisition, closed in late 2021 while still operating as PerkinElmer, added a high-growth, high-margin antibody and reagent franchise with a direct channel to immunology researchers. Post-rebrand, BioLegend remains Revvity's flagship protein-biology platform, and the management team that built it was retained to drive further organic expansion in multiplexed proteomics.
Which sectors does Revvity explicitly avoid?
Revvity explicitly avoids applied markets — food safety testing, environmental analysis, and industrial quality control — which was the entire segment sold to New Mountain Capital. It also does not manufacture therapeutic drugs or provide clinical care, staying strictly on the tools-and-software side of life sciences.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: